Bridgeway Capital Management, LLC Viracta Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.03 - $1.58 $52,530 - $80,580	-51,000 Reduced 40.8%	74,000 $76,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $37,800 - $131,400	30,000 Added 31.58%	125,000 $182,000
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $83,000 - $142,250	25,000 Added 35.71%	95,000 $406,000
Q1 2022 May 16, 2022	BUY	$2.23 - $4.76 $78,050 - $166,600	35,000 Added 100.0%	70,000 $333,000
Q4 2021 Feb 14, 2022	SELL	$3.37 - $7.91 $50,550 - $118,650	-15,000 Reduced 30.0%	35,000 $128,000
Q2 2021 Aug 16, 2021	BUY	$7.55 - $12.95 $377,500 - $647,500	50,000 New	50,000 $567,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.